The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

I.ap

Pulmonary infiltrates

Publications

Kaneko T, Otoshi R, Sekine A, Baba T, Yamada C, Haga S, Tagami Y, Sawazumi T, Takemura T, Komatsu S, Hagiwara E, Ogura T

Drug-related pneumonitis caused by amikacin liposome inhalation suspension: One pathologically proven case and single-center experience.

Respiratory investigation 2024 Jul;62;513-516 — 2024 Jul — 513-516

Takao D, Takeda K, Takazono T, Ozasa M, Ito Y, Ashizawa N, Hirayama T, Iwanaga N, Takemoto S, Ide S, Tashiro M, Hosogaya N, Kido T, Sakamoto N, Obase Y, Okano S, Izumikawa K, Yanagihara K, Mukae H

A case of drug-induced organizing pneumonia caused by amikacin liposome inhalation suspension.

Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy 2023 Aug;29;806-808 — 2023 Aug — 806-808

Kidogawa M, Yamasaki K, Nemoto K, Yatera K

Liposomal Amikacin Inhalation Suspension-induced Pneumonitis.

Internal medicine (Tokyo, Japan) 2022 Feb 01;; — 2022 Feb 01